Brian Barnett, MD is Vice Chair of Psychiatry and Clinical Director of the Psychiatric Treatment-Resistance Program at Cleveland Clinic. He is an Assistant Professor of Psychiatry at Cleveland Clinic Lerner College of Medicine.

Dr. Barnett completed his psychiatry residency at Massachusetts General Hospital and McLean Hospital in 2017. Afterwards, he completed his fellowship in addiction psychiatry at Partners Healthcare in 2018 and a fellowship in forensic psychiatry at University Hospitals/Case Western Reserve University in 2019.

Dr. Barnett’s primary research interests are in psychedelics, mood disorders, and catatonia. He has served as principal investigator on clinical trials evaluating the therapeutic potential of psychedelics for generalized anxiety disorder (LSD), treatment resistant depression (psilocybin), and adjustment disorder (luvesilocin), as well as neuroimaging predictors of antidepressant efficacy for ketamine in patients with treatment resistant bipolar depression. He is site principal investigator on the PCORI-funded Comparative Effectiveness of ECT vs. Ketamine Over the Lifespan (REaKT-SD) trial and a co-investigator on the NIH-funded Ketamine Treatment of Youth Suicide Attempters trial. Additionally, he conducts research on the epidemiology of non-medical psychedelic use.

Dr. Barnett also writes about mental health and addiction issues for the public, and his writing has been featured in Scientific American, the Wall Street Journal, the Washington Post, and other outlets.